Apceth GmbH, of Munich, Germany, received approval to conduct a clinical cancer trial with its genetically modified adult mesenchymal stem cells...The therapy is based on mesenchymal stem cells harvested from the patient's own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient
The company's other main revenue earner at present is the EB66 avian stem cell line, which Vivalis developed as an alternative to cumbersome egg-based vaccine production methods
By Cormac Sheridan | BioWorld International | Wednesday, June 19, 2013
In their work, the authors identified a population of nail stem cells in the nail matrix, a part of the nail bed that is rich in both nerve endings and blood vessels...The authors concluded that nail stem cells "may have the potential to contribute to the development of novel treatments for amputees
The company's other main revenue earner at present is the EB66 avian stem cell line, which Vivalis developed as an alternative to cumbersome egg-based vaccine production methods
By Cormac Sheridan | BioWorld Today | Monday, June 17, 2013
Stem cell therapy Tumor stem cell-specific dendritic cell therapy Hepatocellular carcinoma Achieved 50% enrollment of the total projected enrollment for the Phase I trial 5/23/13 Cytrx Corp. (Los Angeles) Aldoxorubicin A conjugate of doxorubicin Metastatic solid tumors Phase Ib data showed a distribution half-life of 20 hours to 24 hours following infusion, which is significantly longer than doxorubicin's initial half-life of five minutes 5/23/13 DCPrime BV (Amsterdam, the Netherlands) DCP-001
Company (Location) Product Description Indication Status Date AUTOIMMUNE Creabilis SA (Luxembourg) CT327 Topical TrkA kinase inhibitor Chronic pruritis caused by psoriasis Phase IIb data showed a statistically significant and clinically meaningful reduction in pruritus of 60 percent compared to 20 percent for those receiving placebo 5/13/13 Idera Pharmaceuticals Inc. (Cambridge, Mass.) IMO-3100 A selective antagonist of Toll-like receptors 7 and 9 Psoriasis Phase II data showed improvements
Apceth GmbH, of Munich, Germany, received approval to conduct a clinical cancer trial with its genetically modified adult mesenchymal stem cells...The therapy is based on mesenchymal stem cells harvested from the patient's own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient
But the stem cells that need to be treated are in the deep layers of lung tissue, and inhaled gene therapy turned out to replace the faulty gene only in the epithelial cells that line the lungs
By Anette Breindl | BioWorld Today | Thursday, June 13, 2013
Gentium SpA, of Villa Guardia, Italy, filed the documentation requesting a re-examination of the negative opinion given by the European Committee for Medicinal Products for Human Use (CHMP), regarding the marketing authorization for defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy
Sanbio Inc., of Mountain View, Calif., said the FDA has approved its investigational new drug application for the use of SB623, an allogeneic stem cell therapy product, in patients suffering from traumatic brain injuries
SL-401 is a targeted therapy directed to the interleukin-3 receptor present on tumor bulk and cancer stem cells of multiple hematologic cancer indications
Stem Cell Surprise in Myeloproliferation Scientists from the British University of Cambridge have shown that a driver mutation for myeloproliferative neoplasms has an unexpected effect on blood stem cells: It reduces their capacity for self-renewal
